

# 2nd Berlin Conference on IP in Life Sciences 2009: From Biomarkers to Diagnostics

## Programme

---

9:00   Welcome Address	
	H.E. Dr. Peter Boehm, Canadian Ambassador
	Dr. Hans-Rainer Jaenichen, Partner Vossius & Partner
Key Note	
Defining the diagnostic market and its potential	Dr. Christian Peter, Analyst, Sal. Oppenheim
Biomarker Discovery	
Biobanking and Biomolecular Resources Research Infrastructure BBMRI	Georges Dagher, Inserm - Clinical Research and Therapeutics Department
Biomarker Development	
The R&D process in the pharmaceutical industry, developing personalized treatments	Dr. Simon Read, Biomarker and Experimental Medicine Leader, Roche Products Ltd.
10:30   <i>Coffee Break</i>	
11:00   Performance Evaluation	
Accelerating Biomarker Assay Development to Validation	Paul Smith, Vice President - Research Markets, Axela Inc.
Intellectual Property	
Patenting nucleic acid-based biomarkers	Dr. Christian Kilger, Patent Attorney, Vossius & Partner

9:00   Welcome Address		
Regulatory		
The European approval pathway of diagnostic/drug combinations		Jesus Rueda, Regulatory Affairs Manager, EDMA
12:30   Lunch		
13:30   Intellectual Property		
Patenting peptide-based biomarkers		Dr. Ute Kilger, Patent Attorney, Vossius & Partner
Companion Diagnostics		
Diagnostic-based therapeutics in oncology		Dr. Gabriele Beer, Diagnostics Liaison Manager, Oncology, Roche Diagnostics
Imaging		
Combining in-vitro and imaging biomarkers for early detection of Alzheimer's Disease		Dr. Lennart Thurfjell, Director Diagnostic Software, GE Healthcare
15:00   Coffee Break		
15:30   Reimbursement		
Pricing strategies of IVD		Dr. Jürgen Schulze, Managing Director, Sysmex GmbH Chairman, VDPGH e.V.
Marketing		
Marketing strategies of IVD		Dr. Hartmut Goette, Senior Marketing Manager, Qiagen Women's Health
Discussion/wrap up		
Biomarkers and diagnostics: lessons learned		
17:00   Networking		
Cocktail Reception		Invitation Canadian Embassy and Government of Ontario